Esomgel 40
Each enteric coated tablet contains : Esomeprazole Magnesium IP (As Trihydrate) Eq. to Esomeprazole 40mg Excipients q.s.
| Composition | Each enteric coated tablet contains : Esomeprazole Magnesium IP (As Trihydrate) Eq. to Esomeprazole 40mg Excipients q.s. |
| Packing | ALU ALU - 10*10 |
| MRP | ₹85 |
Product Overview
ESOMAG 40 (NEW) is a highly effective proton pump inhibitor containing 40mg of enteric-coated Esomeprazole Magnesium. It provides prolonged control over gastric acid production, accelerating the healing of mucosal linings and offering relief from persistent heartburn. This formulation represents a foundational high-demand product for general practitioners and gastroenterology-focused pharma networks.
Indications
ESOMAG 40 (NEW) is indicated for the definitive management of:
- Gastroesophageal Reflux Disease (GERD): Healing erosive esophagitis and providing long-term maintenance to prevent reflux relapse.
- Peptic Ulcer Disease (PUD): Treating active duodenal or gastric ulcers, and protecting mucosal linings during continuous NSAID use.
- Zollinger-Ellison Syndrome: Managing pathological hypersecretory conditions requiring sustained high-dose acid suppression.
- H. pylori Eradication: Used in combination with target antibiotics to clear Helicobacter pylori infections.
Dosage & Administration
Adults: 1 tablet daily, taken strictly 30 to 60 minutes before breakfast. The tablet must be swallowed whole with water—do not break, crush, or chew, to preserve the enteric coating.
Adverse Effects
Generally well tolerated; potential side effects include:
- Cephalea (headache)
- Diarrhea, abdominal flatulence, or nausea
- Dryness of the mouth
- Transient skin reactions or pruritus
View Complete Medical Information
Contraindications
Contraindicated in patients with known hypersensitivity to esomeprazole, substituted benzimidazoles, or any formulation component. Do not co-administer with antiretroviral agents like nelfinavir or atazanavir.
Warnings & Precautions
Sustained therapy exceeding three months can increase the risk of hypomagnesemia; long-term use exceeding one year may elevate the risk of osteoporotic bone fractures. Symptomatic response to therapy does not rule out the presence of gastric malignancy.
Drug Interactions
By raising gastric pH levels, it can significantly decrease the systemic absorption of ketoconazole, itraconazole, and erlotinib. It may elevate plasma levels of diazepam, citalopram, and warfarin by inhibiting CYP2C19 metabolic pathways.
Storage Instructions
Store below 30°C in the original blister pack to protect from ambient moisture and light.
Product image not available
Request This Product
- WHO-GMP Certified Formulations
- Monopoly Rights Available
- Get bulk pricing & MOQ
+91 9689237122 · replies within hours
Related Products
More products in the ANTACIDS therapeutic category
RABTAB D TAB
Each Enteric Coated Tablet Contains: Rabeprazole Sodium IP 20 mg Domperidome IP 10 mg Excipients q.s.
ALU ALU - 10*10
PANCI INJ
Composition:Each vial contains: Pantoprazole 40 mg
VIAL WITH SODIUM CHLORIDE INJECTION - 1 VIALPack Style: Vial
RABICEL DSR CAP
Each film-coated capsule contains: Rabeprazole Sodium equivalent to Rabeprazole 20 mg Domperidone 30 mg
ALU ALU - 10*10 capsules
Interested in this product?
Contact our team to discuss PCD franchise, bulk orders, or contract manufacturing for your market.